Pipeline
Accelerating therapeutic innovation
We’re leveraging our integrated discovery platform to advance a pipeline of high-value therapies. Our current focus lies on translating the immunological and inflammatory and metabolic adaptations of bats into novel treatment options for humans.
We aim to harness the comparative capabilities of our platform to explore other therapeutic areas, including virology, aging, and cancer.
OUR PIPELINE
Discovery
Lead
Identification
Lead
Optimization
Preclinical
Clinical
IMMUNOLOGY AND INFLAMMATION (I&I)
Inflammasome (ASC)
Discovery
Lead
Identification
Lead
Optimization
Preclinical
Clinical
Target A
Discovery
Lead
Identification
Lead
Optimization
Preclinical
Clinical
CARDIOMETABOLISM
Target A
Discovery
Lead
Identification
Lead
Optimization
Preclinical
Clinical
Target B
Discovery
Lead
Identification
Lead
Optimization
Preclinical
Clinical
Multiple targets
Discovery
Lead
Identification
Lead
Optimization
Preclinical
Clinical
VIROLOGY
Ongoing research collaboration with National Institute of Allergy and Infectious Disease (NIAID)
Therapeutic focus areas
Immunological & inflammatory diseases
The precise mechanisms of many immunological and inflammatory diseases are not fully understood, and identifying effective therapeutic targets remains a challenge. Chronic or uncontrolled inflammation can drive the onset of difficult-to-treat conditions and exacerbate viral symptoms.
Leveraging bat biology to address inflammation:
Bats possess a unique biological adaptation that reduces inflammation and swiftly regulates immune responses, ultimately avoiding the negative effects of prolonged inflammation.
We’re exploring the genomics of these adaptations to discover therapeutic targets for immunologic and inflammatory diseases and gain a deeper understanding of the mechanisms that drive these conditions.
Cardiometabolic diseases
Cardiometabolic diseases involve the interaction of complex pathways that are not fully characterized. There is an urgent need to discover promising targets to address these conditions.
Leveraging bat biology to solve cardiometabolic challenges:
Fruit-eating bats evolved to thrive on high-sugar diets without experiencing adverse health effects. Despite 60% of their diet containing sugar, these bats are able to maintain healthy glucose levels. They can regulate blood sugar levels faster than their insect-eating counterparts. We have much to learn from bats’ extreme cardiovascular range and cardiovascular fitness which are both required to power flight.
We’re exploring the genomics of these adaptations to discover therapeutic targets for cardiometabolic diseases and gain a deeper understanding of the mechanisms that drive these conditions.
Partnerships
Our work is powered by collaborations with academic researchers and drug development experts across the world. We’re seeking partnerships with like-minded institutions to leverage nature’s evolution for the betterment of human health. Interested in partnering with us to unlock the full therapeutic potential of bat biology?